Global Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Market Forecast)

Report Summary

Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.

This report studies the market from 2005 to 2020 covering 21 major drugs categorized into four therapies; namely hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. Out of the whole lot of 21 drugs, 13 are currently commercially available in the market and 8 in pipeline. Growing prostate cancer population (25% increase in the incidence of prostate cancer in mature countries and 40% increase in emerging countries, from 2010 to 2020) is an impetus for the growth of the market. This factor, along with increasing number of innovative drugs estimated to get launched in short-term future and increasing old age male population are driving the growth of the market at an expected CAGR of 9% from 2010 to 2020. In 2010, among the mature markets, the U.S. was the major contributor; accounting for 35% of the total sales of prostate cancer drugs and amongst the emerging countries, China contributed to the share of about 2% of the overall prostate cancer therapeutics market.

As far as drugs are concerned, Taxotere accounted for 23% of the total sales of prostate cancer drugs in 2010. Astrazeneca PLC is the leading market player with the share of 30% in the total prostate cancer therapeutics market, in 2010. However, by 2020, Astrazeneca will lose its market share by 19%, due to entry of new players such as Active Biotech, Bristol Myers-Squibb, Teva Pharmaceuticals Industries Ltd, and Johnson & Johnson (entered the market in 2011, with its key drug Zytiga).

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were certain major strategies adopted by the players from January 2006 to September 2011.

Scope of the report

The prostate cancer therapeutics market research report evaluates the global prostate cancer drugs market with respect to the current and pipeline drugs. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

Global prostate cancer hormonal therapy drugs market -

• LHRH antagonists - Firmagon
• LHRH analogs - Zoladex, Lupron, Eligard, Vantas, and Decapeptyl
• Antiandrogens - Casodex
• Pipeline drugs for hormonal therapy - Zytiga, MDV3100, and TAK700

Global prostate cancer chemotherapy drugs market -

• Off patent drugs - Taxotere, mitoxantrone, and Emcyt
• Patented drugs - Jevtana

Global prostate cancer immunotherapy drugs market-

• Patented drug - Provenge
• Pipeline drug - ipilimumab

Global prostate cancer targeted therapy drugs market-

• Angiogenesis inhibitor - lanreotide, TASQ, Zaltrap
• Apoptosis inducing - custirsen sodium
• Signal transduction inhibitor - Sprycel

The geographies covered under the report are -

North America

•  
• U.S.
• Canada

Europe

• U.K.
• Germany
• Italy
• France
• Spain

Emerging countries

• Brazil
• Russia
• India
• China
• Turkey
• South Korea

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings, and future forecasts in consideration.

Table Of Contents

1 INTRODUCTION
1.1KEY TAKE-AWAYS
1.2REPORT DESCRIPTION
1.3MARKETS COVERED
1.4STAKEHOLDERS
1.5RESEARCH METHODOLOGY
1.5.1MARKET SIZE
1.5.2MARKET SHARE
1.5.3KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1DEFINING PROSTATE CANCER
3.1.1RISK FACTORS
3.1.1.1Age
3.1.1.2Race
3.1.1.3Family history/genetics
3.1.1.4Diet/lifestyle factors
3.1.1.5Obesity
3.1.1.6Infection/Inflammation of the prostate gland
3.1.2DISEASE SYMPTOMS
3.1.3DIAGNOSIS
3.1.3.1Digital rectal exam (DRE)
3.1.3.2Prostate specific antigen (PSA) blood test
3.1.3.3Prostate biopsy
3.1.3.4Ultrasound
3.1.3.5Bone scan
3.1.3.6CT scan & MRI
3.1.3.7PET & SPECT scan
3.1.3.8Lymph node biopsy
3.1.3.9ProstaScint monoclonal antibody scan
3.1.4PROSTATE CANCER PREVALENCE
3.1.5INCIDENCE & MORTALITY
3.2STAGES OF PROSTATE CANCER
3.2.1STAGE I
3.2.2STAGE II
3.2.3STAGE III
3.2.4STAGE IV
3.3MARKET STRUCTURE
3.3.1KEY THERAPIES
3.3.1.1Chemotherapy
3.3.1.2Hormonal therapy
3.3.1.3Immunotherapy
3.3.1.4Targeted therapy

4 MARKET DYNAMICS
4.1INTRODUCTION
4.2DRIVERS
4.2.1INNOVATIVE DRUGS DRIVING THE MARKET
4.2.2INCREASE IN RESEARCH & DEVELOPMENT IN ONCOLOGY THERAPEUTIC AREA
4.2.3DEVELOPMENTS IN GENOMICS & PROTEOMICS
4.3RESTRAINTS
4.3.1ADVERSE EVENTS OF TREATMENT
4.3.2COST ASSOCIATED WITH THE TREATMENT
4.3.3INCREASING ADOPTION OF VALUE BASED MEDICINE CONCEPT IN MAJOR MARKETS
4.3.4LOW SUCCESS RATE IN CLINICAL TESTING FOR ONCOLOGY DRUGS
4.4OPPORTUNITIES
4.4.1LIMITED PLAYERS IN THE MARKET
4.4.2GROWING OLDER MALE POPULATION
4.4.3OFF LABEL PRESCRIPTION FOR PROSTATE CANCER
4.4.4TREND OF INCREASE IN PHARMACEUTICAL EXPENDITURE BY EMERGING MARKETS
4.4.5ONCOLOGY IS THE LARGEST THERAPEUTIC MARKET WITH HIGH UNMET NEEDS
4.5MARKET SHARE
4.5.1BY COMPANY
4.5.2BY GEOGRAPHY
4.5.3BY THERAPY
4.6BURNING ISSUES
4.6.1HIGH COST OF TREATMENT RELATIVE TO MODEST DRUG BENEFIT
4.6.2ESTIMATED INCREASE IN COMPETITION DUE TO ADDITION OF PROSTATE CANCER INDICATION TO EXISTING DRUGS
4.7WINNING IMPERATIVES
4.7.1STRATEGY OF GEOGRAPHICAL EXPANSION IN EMERGING MARKETS
4.7.2STRATEGY OF PRODUCT EDUCATION COUPLED WITH PRODUCTION CAPACITY EXPANSION

5 PRODUCT MARKET
5.1HORMONAL THERAPY
5.1.1LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANTAGONISTS
5.1.1.1FIRMAGON
5.1.2LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOGS
5.1.2.1LUPRON
5.1.2.2ZOLADEX
5.1.2.3DECAPEPTYL
5.1.2.4ELIGARD
5.1.2.5VANTAS
5.1.3ANTI-ANDROGENS
5.1.3.1CASODEX
5.2CHEMOTHERAPY
5.2.1TAXOTERE
5.2.2JEVTANA
5.2.3MITOXANTRONE (NOVANTRONE)
5.2.4ESTRAMUSTINE (EMCYT)
5.3IMMUNOTHERAPY
5.3.1PROVENGE

6 PIPELINE DRUGS MARKET
6.1HORMONAL THERAPY
6.1.1ABIRATERONE ACETATE
6.1.2MDV3100
6.1.3TAK700
6.2TARGETED THERAPY
6.2.1ANGIOGENESIS INHIBITORS
6.2.1.1LANREOTIDE
6.2.1.2TASQUINIMOD (TASQ)
6.2.1.3ZALTRAP
6.2.2APOPTOSIS INDUCING
6.2.2.1CUSTIRSEN SODIUM
6.2.3SIGNAL TRANSDUCTION INHIBITOR
6.2.3.1SPRYCEL
6.3IMMUNOTHERAPY
6.3.1IPILIMUMAB

7 GEOGRAPHICAL ANALYSIS
7.1INTRODUCTION
7.2NORTH AMERICA
7.2.1U.S.
7.2.2CANADA
7.3EUROPE
7.3.1U.K.
7.3.2GERMANY
7.3.3FRANCE
7.3.4ITALY
7.3.5SPAIN
7.4JAPAN
7.5EMERGING MARKETS
7.5.1BRAZIL
7.5.2RUSSIA
7.5.3INDIA
7.5.4CHINA
7.5.5TURKEY
7.5.6SOUTH KOREA

8 COMPETITIVE LANDSCAPE
8.1KEY STRATEGIES

9 COMPANY PROFILES
9.1ABBOTT LABORATORIES
9.1.1OVERVIEW
9.1.2PRODUCTS & SERVICES
9.1.3FINANCIALS
9.1.4STRATEGY
9.1.5DEVELOPMENTS
9.2ACTIVE BIOTECH
9.2.1OVERVIEW
9.2.2PRODUCTS & SERVICES
9.2.3FINANCIALS
9.2.4STRATEGY
9.2.5DEVELOPMENTS
9.3ASTRAZENECA PLC
9.3.1OVERVIEW
9.3.2PRODUCTS & SERVICES
9.3.3FINANCIALS
9.3.4STRATEGY
9.3.5DEVELOPMENT
9.4ASTELLAS PHARMA INC
9.4.1OVERVIEW
9.4.2PRODUCTS & SERVICES
9.4.3FINANCIALS
9.4.4STRATEGY
9.4.5DEVELOPMENTS
9.5BRISTOL-MYERS SQUIBB
9.5.1OVERVIEW
9.5.2PRODUCTS & SERVICES
9.5.3FINANCIALS
9.5.4STRATEGY
9.5.5DEVELOPMENTS
9.6DENDREON CORPORATION
9.6.1OVERVIEW
9.6.2PRODUCTS & SERVICES
9.6.3FINANCIALS
9.6.4STRATEGY
9.6.5DEVELOPMENTS
9.7ENDO PHARMACEUTICALS INC (INDEVUS PHARMACEUTICALS INC)
9.7.1OVERVIEW
9.7.2PRODUCTS & SERVICES
9.7.3FINANCIALS
9.7.4STRATEGY
9.7.5DEVELOPMENTS
9.8IPSEN
9.8.1OVERVIEW
9.8.2PRODUCTS & SERVICES
9.8.3FINANCIALS
9.8.4STRATEGY
9.8.5DEVELOPMENTS
9.9JOHNSON & JOHNSON
9.9.1OVERVIEW
9.9.2PRODUCTS & SERVICES
9.9.3FINANCIALS
9.9.4STRATEGY
9.9.5DEVELOPMENTS
9.10PFIZER INC
9.10.1OVERVIEW
9.10.2PRODUCTS & SERVICES
9.10.3FINANCIALS
9.10.4STRATEGY
9.10.5DEVELOPMENTS
9.11SANOFI-AVENTIS
9.11.1OVERVIEW
9.11.2PRODUCTS & SERVICES:
9.11.3FINANCIALS
9.11.4STRATEGY
9.11.5DEVELOPMENTS
9.12TEVA PHARMACEUTICAL INDUSTRIES LTD
9.12.1OVERVIEW
9.12.2PRODUCTS & SERVICES
9.12.3FINANCIALS
9.12.4STRATEGY
9.12.5DEVELOPMENTS
9.13TAKEDA PHARMACEUTICAL CO. LTD
9.13.1OVERVIEW
9.13.2PRODUCTS & SERVICES
9.13.3FINANCIALS
9.13.4STRATEGY
9.13.5DEVELOPMENTS
9.14OTHERS
9.14.1FERRING PHARMACEUTICALS
9.14.1.1OVERVIEW
9.14.1.2PRODUCTS & SERVICES
9.14.1.3FINANCIALS
9.14.1.4STRATEGY
9.14.1.5DEVELOPMENTS
9.14.2TOLMAR INC
9.14.2.1OVERVIEW
9.14.2.2PRODUCTS & SERVICES
9.14.2.3FINANCIALS
9.14.2.4STRATEGY
9.14.2.5DEVELOPMENTS

List Of Tables

TABLE 1GLOBAL PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 – 2020 ($MILLION)
TABLE 2CHEMOTHERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 3CHEMOTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 4HORMONAL THERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 5HORMONAL THERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 6IMMUNOTHERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 7IMMUNOTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 8TARGETED THERAPY MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($MILLION)
TABLE 9TARGETED THERAPY MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 10FIRMAGON MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 11FIRMAGON MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 12LUPRON MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 13LUPRON MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 14ZOLADEX MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 15ZOLADEX MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 16DECAPEPTYL MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 17DECAPEPTYL MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 18ELIGARD MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 19ELIGARD MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 20VANTAS MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 21VANTAS MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 22CASODEX MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 23CASODEX MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 24TAXOTERE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 25TAXOTERE MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 26JEVTANA MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 27JEVTANA MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 28MITOXANTRONE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 29MITOXANTRONE MARKET REVENUE, BY GEOGRAPHY, 2005-2020 ($THOUSAND)
TABLE 30EMCYT MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 31EMCYT MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 32PROVENGE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 33PROVENGE MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 34ABIRATERONE ACETATE MARKET REVENUE , BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 35ABIRATERONE ACETATE MARKET REVENUE, BY COUNTRY, 2015 - 2020 ($THOUSAND)
TABLE 36MDV3100 MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 37MDV3100 MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 38TAK700 MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 39TAK700 MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 40LANREOTIDE MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 41LANREOTIDE MARKET REVENUE, BY COUNTRY, 2015 - 2020 ($THOUSAND)
TABLE 42TASQUINIMOD MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 43TASQUINIMOD MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 44ZALTRAP MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 45ZALTRAP MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 46CUSTIRSEN SODIUM MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 47CUSTIRSEN SODIUM MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 48SPRYCEL MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 49SPRYCEL MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 50IPILIMUMAB MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($THOUSAND)
TABLE 51IPILIMUMAB MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($THOUSAND)
TABLE 52PROSTATE CANCER DRUGS MARKET REVENUE, BY GEOGRAPHY, 2005 - 2020 ($MILLION)
TABLE 53PROSTATE CANCER DRUGS MARKET REVENUE, BY COUNTRY, 2005 - 2020 ($MILLION)
TABLE 54NORTH AMERICA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 55U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 56U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 57CANADA PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 58CANADA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 59EUROPE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 60U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 61U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 62GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 63GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 64FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY 2005 - 2020 ($THOUSAND)
TABLE 65FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 66ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 67ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 68SPAIN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 69SPAIN: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 70JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 71JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 72EMERGING MARKETS: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 73BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 74BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 75RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 76RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 77INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 78INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 79CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 80CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 81TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 82TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 83SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2005 - 2020 ($THOUSAND)
TABLE 84SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY PRODUCTS, 2005 - 2020 ($THOUSAND)
TABLE 85KEY COMPANIES FOCUSING ON DEVELOPMENT OF PIPELINE DRUGS
TABLE 86KEY COMPANIES FOCUSING ON COMMERCIALIZATION OF NEW PRODUCTS
TABLE 87ACQUISITIONS & MERGERS, 2009 - 2011
TABLE 88COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES, 2008 - 2011
TABLE 89NEW PRODUCTS DEVELOPMENT, 2009 - 2011
TABLE 90EXPANSION/NEW FACILITY/INVESTMENT, 2009
TABLE 91FDA APPROVALS/GOVERNMENT GRANTS, 2008 - 2011
TABLE 92PRECLINICAL STUDY, 2008 - 2011
TABLE 93CLINICAL TRIALS - PHASE I
TABLE 94CLINICAL TRIALS - PHASE II
TABLE 95CLINICAL TRIALS - PHASE III
TABLE 96NEW DRUG APPLICATION & MARKETING AUTHORIZATION APPLICATION, 2008 - 2011
TABLE 97OTHERS, 2008 – 2011
TABLE 98ABBOTT: SALES AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 99ACTIVE BIOTECH: RESEARCH REVENUE AND R&D EXPENSES 2008 – 2010 ($MILLION)
TABLE 100ASTRAZENECA PLC: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 101ASTRAZENECA PLC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 102ASTRAZENECA PLC: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 103ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 104ASTELLAS PHARMA INC: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 105ASTELLAS PHARMA INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 106ASTELLAS PHARMA INC: SALES, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 107 BRISTOL-MYERS SQUIBB: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 108BRISTOL-MYERS SQUIBB: SALES AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 109BRISTOL-MYERS SQUIBB: SALES, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 110BRISTOL-MYERS SQUIBB: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2009 ($MILLION)
TABLE 111DENDREON CORPORATION: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 112ENDO PHARMACEUTICALS INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 113ENDO PHARMACEUTICALS INC: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 114IPSEN: R&D PIPELINE FOR PROSTATE CANCER TREATMENT
TABLE 115IPSEN: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
TABLE 116IPSEN: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 117IPSEN: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 118JOHNSON & JOHNSON: REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 119JOHNSON & JOHNSON: REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 120JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($BILLION)
TABLE 121PFIZER INC: REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 122PFIZER INC: REVENUE BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 123PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 124SANOFI-AVENTIS: SALES AND R&D EXPENSES, 2008 - 2010 ($MILLION)
TABLE 125SANOFI-AVENTIS: SALES, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
TABLE 126SANOFI-AVENTIS: SALES, BY GEOGRAPHY, 2009 - 2010 ($MILLION)
TABLE 127TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE AND R&D EXPENSES 2008 - 2010 ($MILLION)
TABLE 128TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
TABLE 129TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY BUSINESS SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 130TAKEDA PHARMACEUTICALS: REVENUE AND R&D EXPENSES, 2008 - 2011 ($MILLION)
TABLE 131TAKEDA PHARMACEUTICALS: REVENUE, BY GEOGRAPHY, 2008 - 2011 ($MILLION)
TABLE 132TAKEDA PHARMACEUTICALS: REVENUE, BY BUSINESS SEGMENTS, 2008 - 2010 ($MILLION)
 
List Of Figures

FIGURE 1 PROSTATE CANCER DISEASE OVERVIEW
FIGURE 2 PROSTATE CANCER ABSOLUTE INCIDENCE, BY COUNTRY, 2010 & 2020
FIGURE 3 PROSTATE CANCER INCIDENCE & MORTALITY (PER 100,000 MALES), BY COUNTRY, 2008
FIGURE 4 PROSTATE CANCER TREATMENT OPTIONS, BY STAGES
FIGURE 5 PROSTATE CANCER DRUGS: MARKET SEGMENTATION, BY THERAPY
FIGURE 6 CHEMOTHERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 7 HORMONAL THERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 8 IMMUNOTHERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 9 TARGETED THERAPY DRUGS: MARKET SEGMENTATION, BY DRUGS
FIGURE 10 PROSTATE CANCER TREATMENT OPTIONS, BY THERAPY
FIGURE 11 CHEMOTHERAPY MARKET SHARE, BY GEOGRAPHY, 2010 – 2020
FIGURE 12 HORMONAL THERAPY MARKET SHARE, BY GEOGRAPHY, 2010 – 2020
FIGURE 13 IMMUNOTHERAPY MARKET SHARE, BY GEOGRAPHY, 2015 & 2020
FIGURE 14 TARGETED THERAPY MARKET SHARE, BY GEOGRAPHY, 2015 & 2020
FIGURE 15 DISTRIBUTION OF GLOBAL R&D PROJECTS, BY THERAPEUTIC SEGMENTS, 2010 (%)
FIGURE 16 SUCCESS RATE IN CLINICAL TRIALS, BY CANCER TYPES
FIGURE 17 FAILURE RATE OF CANCER DRUGS VS NON CANCER DRUGS (PHASE WISE)
FIGURE 18 GROWING MALE POPULATION, 2010 – 2050
FIGURE 19 EXPENDITURE ON MEDICINES, BY GEOGRAPHY, 2010 VS 2015
FIGURE 20 MARKET REVENUE, BY TOP 10 THERAPEUTIC SEGMENTS ($BILLION)
FIGURE 21 MARKET SHARE, BY COMPANY, 2010 VS 2020 (%)
FIGURE 22 MARKET SHARE, BY GEOGRAPHY, 2010 VS 2020 (%)
FIGURE 23 MARKET SHARE, BY THERAPY, 2010 VS 2020 (%)
FIGURE 24 U.S: PREVALENCE & INCIDENCE OF PROSTATE CANCER, 2008 – 2020
FIGURE 25 U.S: CANCER CARE EXPENDITURES FOR TOP FIVE CANCER SITES,  2010 & 2020 ($BILLION)
FIGURE 26 U.S: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 27 CANADA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 28 U.K: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 29 GERMANY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 30 FRANCE: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 31 ITALY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 32 SPAIN: PROSTATE CANCER DRUGS MARKET, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 33 JAPAN: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 34 BRAZIL: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 35 RUSSIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 36 INDIA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 37 CHINA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 38 TURKEY: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 39 SOUTH KOREA: PROSTATE CANCER DRUGS MARKET REVENUE, BY THERAPY, 2010 & 2020 ($THOUSAND)
FIGURE 40 GROWTH STRATEGIES, 2008 - 2011
FIGURE 41 ACTIVE BIOTECH: PIPELINE PRODUCTS, BY THERAPY AREA, 2010
FIGURE 42 ASTRAZENECA PLC: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 – 2010 (%)
FIGURE 43 ASTRAZENECA PLC: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 44 ASTELLAS PHARMA INC: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 45 BRISTOL-MYERS SQUIBB: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 46 BRISTOL-MYERS SQUIBB: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 47 IPSEN: SHARE OF GEOGRAPHIC REVENUE IN TOTAL REVENUE, 2009 VS 2010
FIGURE 48 JOHNSON & JOHNSON: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010
FIGURE 49 PFIZER INC: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010 (%)
FIGURE 50 SANOFI-AVENTIS: SHARE OF BUSINESS SEGMENTS IN TOTAL REVENUE, 2009 VS 2010
FIGURE 51 SANOFI-AVENTIS: SALES, BY GEOGRAPHY 2009 VS 2010 ($MILLION)
FIGURE 52 TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE, BY GEOGRAPHY, 2009 VS 2010 ($MILLION)
FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD: SHARE OF BUSINESS SEGMENTS IN TOTAL SALES, 2009 VS 2010 (%)
FIGURE 54 TAKEDA PHARMACEUTICALS: REVENUE, BY GEOGRAPHY, 2009 - 2010 ($MILLION)